References
- Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/Progestin Replacement Study (HERS) Research Group. J Am Med Assoc 1998; 280:605–13
- Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med 2004;350: 991–1004
- The Writing Group for the Women's Health Initia-tive Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: princi-pal results from the Women's Health Initiative randomized controlled trial. J Am Med Assoc 2002; 288:321–33
- Genazzani AR, Gambacciani M. The sound of an international anti-HRT herald. Maturitas 2003;46: 105–6
- Genazzani AR, Gambacciani M. A personal initiative for women's health: to challenge the Women's Health Initiative. Gynecol Endocrinol 2002;16:255–7
- Gambacciani M, Rosano G, Monteleone P, et al. Clinical relevance of the HERS trial. Lancet 2002; 360:641
- Gambacciani M, Genazzani AR. The Christmas present for women's health: a strike to osteoporosis prevention. Maturitas 2004;48:in press
- Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epi-demiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350:1047–59
- Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 2003; 362:419–27
- Gambacciani M, Genazzani AR. The study with a million women (and hopefully fewer mistakes). Gynecol Endocrinol 2003;17:359–62
- Simoncini T, Genazzani AR. Direct vascular effects of estrogens and selective estrogen receptor modulators. Cum Opin Obstet Gynecol 2000;12:181–7
- Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med 1999;340:1801–11
- Mendelsohn ME, Karas RH. The time has come to stop letting the HERS tale wag the dogma. Circulation 2001;104:2256–9
- Psaty BM, Smith NL, Lemaitre RN, et al. Hormone replacement therapy, prothrombotic mutations, and the risk of incident nonfatal myocardial infarction in postmenopausal women. J Am Med Assoc 2001;285: 906–13
- Shearman AM, Cupples LA, Demissie S, et al. Associa-tion between estrogen receptor alpha gene variation and cardiovascular disease. J Am Med Assoc 2003; 290:2263–70
- Utian WH, Shoupe D, Bachmann G, et al. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. Fertil Steril 2001;75: 1065–79
- Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. JAm Med Assoc 2002;287:2668–76
- Archer DF, Dorin M, Lewis V, et al. Effects of lower doses of conjugated equine estrogens and medroxy-progesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–7
- Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001;76:13–24
- Gambacciani M, Genazzani AR. Hormone replace-ment therapy: the benefits in tailoring the regimen and dose. Maturitas 2001;40:195–201.